Oral Cavity Squamous Cell Carcinoma Clinical Trials

45 clinical trials for Oral Cavity Squamous Cell Carcinoma across international registries, including 10 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer — RECRUITING · PHASE2
• Study Comparing Limited and Extensive Neck Surgery in Oral Cancer Patients With Neck Spread — RECRUITING · NA
• Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel — RECRUITING
• Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial — RECRUITING · PHASE2
• Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation — RECRUITING · NA
• Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer — RECRUITING · PHASE2
• Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer — RECRUITING · PHASE2
• Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer — RECRUITING · PHASE2
• Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC) — RECRUITING · PHASE1
• Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) — RECRUITING · PHASE2
• Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin — COMPLETED · PHASE2
• Tolerability and efficacy of treating locally advanced Resectable Oral Cancer with neoadjuvant INtratumoral anti-CTLA4 ImmunoTherapy combined with systemic anti-PD-1 (ROCinIT). — NOT_YET_RECRUITING · PHASE2
• First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients — ACTIVE_NOT_RECRUITING · PHASE2
• APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma — NOT_YET_RECRUITING · PHASE3
• Evaluating the Optimal Timing of Acupuncture for Managing Chemoradiation-induced Xerostomia in Patients With Head and Neck Cancers — NOT_YET_RECRUITING · NA
• Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). — ACTIVE_NOT_RECRUITING · PHASE2
• H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC) — NOT_YET_RECRUITING · PHASE2
• Artificial Intelligence for the Diagnosis of Oral Lesions — NOT_YET_RECRUITING
• A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery — TERMINATED · PHASE1
• Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma — NOT_YET_RECRUITING · PHASE1
• Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM) — TERMINATED · NA
• Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck. — TERMINATED · PHASE2
• IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma — COMPLETED · PHASE1
• Study Comparing Fibula Free-flap MR With or Without PVP in Patients With OOPC — COMPLETED · NA
• Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck — ACTIVE_NOT_RECRUITING · PHASE2
• Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma — COMPLETED · PHASE1
• Helical CT, PET/CT, MRI, and CBCT Alone or in Combination in Predicting Jaw Invasion in Patients With Oral Cancer — TERMINATED
• Sentinel Node Biopsy in Early Oral Cancers a Tertiary Cancer Centre Experience — COMPLETED · NA
• WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer — COMPLETED · PHASE1
• Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer — WITHDRAWN · PHASE2
• Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity — OTHER · PHASE1
• Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer — COMPLETED · PHASE2
• Biofeedback Rehabilitation to Improve Speaking and Eating in Public — COMPLETED · NA
• A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers — WITHDRAWN · PHASE1
• Articulatory Adaptation Following Oral Cancer Treatment — OTHER
• Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy — TERMINATED · PHASE1
• A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma — OTHER · PHASE2
• Efficacy and Safety of Neoadjuvant Pembrolizumab in III-IVA Resectable Oral Squamous Cell Carcinoma — OTHER
• Saliva-based Detection of CD44 — COMPLETED
• Metformin in Head and Neck Squamous Cell Carcinoma: Effect on Tissue Oxygenation — COMPLETED · NA
• Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction — OTHER · PHASE1
• Feasibility of CTCs Isolation for Transcriptomes and Genome Wide Associated Analysis in Post-OP High Risk OSCC Patients. — OTHER
• Radioguided Selective Neck Dissection for Staging and Treatment of Oral Cavity and Oropharyngeal Squamous Cell Carcinoma — OTHER
• Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients — OTHER
• Identification of Breath Biomarkers in Head and Neck Squamous Cell Carcinoma — SUSPENDED

Refine this search